高尿酸血症患者における水素水摂取が血中尿酸値に及ぼす影響：無作為化プラセボ対照試験
A randomized, placebo-controlled trial enrolled 100 patients with hyperuricemia, divided into three groups: placebo (ordinary water, 3×330 mL/day), low-dose hydrogen-rich water (HRW; 2×330 mL HRW with H₂ ≥4.66 mg/L plus 1×330 mL ordinary water/day), and high-dose HRW (3×330 mL HRW/day), each for 8 weeks. Blood uric acid was measured at baseline, 4 weeks, and 8 weeks. After 8 weeks, the high-dose group showed a statistically significant decline in uric acid from 488.2±54.1 μmol/L to 446.8±57.1 μmol/L (p<0.05), with a greater magnitude of reduction compared to the low-dose group. No notable safety concerns were identified. These results suggest that sustained, higher-dose HRW consumption may offer a feasible approach to managing elevated uric acid levels.
The authors attribute the uric acid-lowering effect to the anti-inflammatory and metabolic-modulatory properties of dissolved molecular hydrogen, though the precise biochemical pathway was not investigated in this trial.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/39258191